424B3PROSPECTUS
Sep 10, 2026Final prospectus0001213900-26-098801
Sources: sec-harvest
No live market is quoted for Adaptin Bio Inc yet. Get in line for IPO-day access through a broker in the meantime.
Invest in stocks once they list with eToro
Trade stocks, ETFs and crypto from one simple account.
From SEC filings, latest FY ending Dec 31, 2025 · CIK 0001938571.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating income | -$5.41M | -$2.57M | -$85.59K | — |
| Net income | -$5.17M | -$3.12M | -$85.59K | — |
| R&D expense | $1.77M | $1.82M | — | — |
| Cash & equivalents | $459.17K | $34.09K | $380 | $500 |
| Total assets | $619.16K | $239.42K | $380 | $500 |
| Total liabilities | $2.11M | $4.34M | $113.28K | $27.8K |
| Shareholders' equity | -$1.49M | -$4.1M | -$977.56K | -$27.3K |
EDGAR filings resolved from APTN / CIK 0001938571.